Why the study?
What is the incidence of neuroleptic malignant syndrome in psychiatric inpatients treated with a single antipsychotic agent?
What is the incidence of neuroleptic malignant syndrome in psychiatric inpatients treated with a single antipsychotic agent?
This is the authors' abstract. We don't add key points for this paper.
The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly over-represented in the NMS group.
Answers are grounded in this paper and cite their sources.
The incidence of neuroleptic malignant syndrome in psychiatric inpatients on single antipsychotic therapy without anticholinergic prophylaxis is approximately 2.2%, with higher risk observed in bipolar patients and those receiving injections.
No takes yet. Share an insight, caveat, or question.
Hermesh et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: